{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antivirals&page=2",
    "query": {
      "intervention": "Oral antivirals",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 235,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antivirals&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antivirals&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T01:11:00.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03491553",
      "title": "Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Selgantolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B virus (HBV) OAV Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2018-04-06",
      "completion_date": "2020-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-08-19",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491553"
    },
    {
      "nct_id": "NCT07115368",
      "title": "Study of GS-1219 in Participants With HIV-1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "GS-1219",
          "type": "DRUG"
        },
        {
          "name": "BVY",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2025-08-11",
      "completion_date": "2025-10-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115368"
    },
    {
      "nct_id": "NCT01964755",
      "title": "Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein Barr Virus Associated Non Hodgkin's Lymphoma",
        "Epstein Barr Virus Associated Hodgkin's Lymphoma",
        "Post-Transplant Lymphoproliferative Disease"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2009-04-21",
      "completion_date": "2018-06-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01964755"
    },
    {
      "nct_id": "NCT00002373",
      "title": "The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Maribavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaxo Wellcome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 56,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002373"
    },
    {
      "nct_id": "NCT01651494",
      "title": "Influenza Antiviral DAS-181-F04 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "DAS181",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-08-12",
      "completion_date": "2012-09-18",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01651494"
    },
    {
      "nct_id": "NCT01552369",
      "title": "CMV Antiviral Prevention Strategies in D+R-Liver Transplants (\"CAPSIL\")",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 205,
      "start_date": "2012-10-29",
      "completion_date": "2018-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-08-26",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552369"
    },
    {
      "nct_id": "NCT00000981",
      "title": "The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Fiacitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "13 Years to 65 Years"
      },
      "enrollment_count": 78,
      "start_date": null,
      "completion_date": "1993-02",
      "has_results": false,
      "last_update_posted_date": "2012-12-18",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000981"
    },
    {
      "nct_id": "NCT03332095",
      "title": "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral (ARV) medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2018-07-02",
      "completion_date": "2022-05-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332095"
    },
    {
      "nct_id": "NCT03004183",
      "title": "SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-small Cell Lung Cancer",
        "Metastatic Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ADV/HSV-tk",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2017-07-01",
      "completion_date": "2024-01-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03004183"
    },
    {
      "nct_id": "NCT00391768",
      "title": "Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "oseltamivir (Tamiflu®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "Up to 23 Months"
      },
      "enrollment_count": 87,
      "start_date": "2007-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-10-01T01:11:00.857Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391768"
    }
  ]
}